Reviewing Inovio Pharmaceuticals (NASDAQ:INO) and Encision (NASDAQ:ECIA)

Inovio Pharmaceuticals (NASDAQ:INO) and Encision (OTCMKTS:ECIA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Volatility and Risk

Inovio Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Encision has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Inovio Pharmaceuticals and Encision, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals 0 0 5 0 3.00
Encision 0 0 0 0 N/A

Inovio Pharmaceuticals currently has a consensus target price of $7.32, indicating a potential upside of 235.96%. Given Inovio Pharmaceuticals’ higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Encision.

Profitability

This table compares Inovio Pharmaceuticals and Encision’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals -1,560.70% -142.10% -74.25%
Encision -5.25% -18.76% -11.86%

Institutional and Insider Ownership

46.2% of Inovio Pharmaceuticals shares are owned by institutional investors. 7.9% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 35.7% of Encision shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Inovio Pharmaceuticals and Encision’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inovio Pharmaceuticals $30.48 million 7.08 -$96.97 million ($1.05) -2.08
Encision $8.80 million 0.47 -$240,000.00 N/A N/A

Encision has lower revenue, but higher earnings than Inovio Pharmaceuticals.

Summary

Inovio Pharmaceuticals beats Encision on 6 of the 11 factors compared between the two stocks.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Encision Company Profile

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The company's AEM instruments product line includes a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also provides various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; and AEM Burn Protection Cable, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was founded in 1991 and is based in Boulder, Colorado.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.